Cullinan Therapeutics (CGEM) Tax Provisions (2022 - 2023)
Cullinan Therapeutics (CGEM) posted quarterly Tax Provisions of $14.1 million for Q4 2023, up 842.11% year-over-year from $1.5 million in Q4 2022, and up 842.11% quarter-over-quarter from -$1.9 million in Q4 2022.
Powered by 
Analysis
Cullinan Therapeutics (CGEM) Tax Provisions (2022 - 2023) Analysis & Trends
Cullinan Therapeutics' Tax Provisions history runs 2 years deep, the most recent figure standing at $14.1 million for Q4 2023.
- In Q4 2023, Tax Provisions rose 842.11% year-over-year to $14.1 million; the TTM figure through Dec 2023 stood at $14.1 million (down 66.49% YoY), while the FY2024 annual figure was -$35.3 million, down 350.45% from the prior year.
- Tax Provisions for Q4 2023 stood at $14.1 million, up from -$1.9 million in the prior quarter.
- The five-year high for Tax Provisions was $66.1 million in Q2 2022, with the low at -$19.6 million in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Cullinan Therapeutics | 1.37 Bn | 1.37 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -14.12 Mn |
| Dec 31, 2022 | -1.88 Mn |
| Sep 30, 2022 | -2.52 Mn |
| Jun 30, 2022 | 66.07 Mn |
| Mar 31, 2022 | -19.60 Mn |